Alivus Life Sciences Performance Analyzed

Alivus Life Sciences, a company that makes special medicines and helps other drug companies develop them, saw its stock price jump by 5.3% on the stock market. The stock reached a high of ₹908, and was trading at ₹889.15 at 11:52 AM. Meanwhile, the overall market (BSE Sensex) went up by 0.4%. This increase happened after the company announced how well they did during the last three months of the year – called Q3FY26.

Key Points

• Alivus’ stock rose 5.3% due to strong Q3 results.
• Profit after taxes increased by 9.7% year-over-year to ₹150.3 crore.
• Revenue grew by 9.6% year-over-year to ₹672.9 crore.
• Ebitda (profit before taxes, interest, and depreciation) jumped 24.7% year-over-year.
• Generic medicine sales grew 11.1% quarter-over-quarter.
• The CDMO business recovered strongly, with 100% revenue growth.

Company Overview

Alivus Life Sciences specializes in making specific, important medicines for long-term health problems like heart issues, brain disorders, pain relief, and diabetes. They also help other companies develop and make their medicines. They work with big drug companies around the world.

Financial Highlights (Q3FY26)

The company’s profits increased significantly, rising to ₹150.3 crore, up from ₹137 crore the previous year. Revenue also grew to ₹672.9 crore. They made a lot of money from their medicines and their help for other companies.

Their profitability also improved, with an Ebitda margin of 36.4%, much higher than the previous year’s 31.3%. This shows they’re managing their costs and making good profits.

Growth Areas

The company is seeing growth in two main areas: making the special medicines themselves (Generic APIs) and helping other companies develop and make their medicines (CDMO services). They’re expanding their business to many countries, including India, Europe, North America, and Japan.

The CFO, Tushar Mistry, highlighted the company’s focus on sustainable growth and its strong financial position – they’re debt-free and have a lot of cash.

“Our strong performance demonstrates our ability to deliver value and build a sustainable future.”